Ohio State Study of Brain Pacemaker Shows Promise in Slowing Decline of Alzheimer’s
January 30, 2018
Columbus, US – While most treatments for Alzheimer’s disease focus on improving memory, researchers at The Ohio State University Wexner Medical Center conducted a study aimed at slowing the decline of problem solving and decision-making skills in these patients. Findings of the study are published in the Journal of Alzheimer’s Disease.
Thin electrical wires were surgically implanted into the frontal lobes of the brains of patients with Alzheimer’s disease to determine if using a brain pacemaker could improve cognitive, behavioral, and functional abilities in patients with this form of dementia. The deep brain stimulation (DBS) implant is similar to a cardiac pacemaker device, except that the pacemaker wires are implanted in specific regions of the brain rather than the heart. This is the first use of DBS in Alzheimer’s disease in a behavioral regulation brain region target.
“We have many memory aids, tools and pharmaceutical treatments to help Alzheimer’s patients with memory, but we don’t have anything to help with improving their judgments, making good decisions, or increasing their ability to selectively focus attention on the task at hand and avoid distractions. These skills are necessary in performing daily tasks such as making the bed, choosing what to eat and having meaningful socializing with friends and family,” said Dr. Douglas Scharre, co-author of the study and director of the Division of Cognitive Neurology at Ohio State’s Wexner Medical Cente’s Neurological Institute.
“The frontal lobes are responsible for our abilities to solve problems, organize and plan, and utilize good judgments. By stimulating this region of the brain, the Alzheimer’s subjects cognitive and daily functional abilities as a whole declined more slowly than Alzheimer’s patients in a matched comparison group not being treated with DBS,” he said. The pilot study found that DBS targeting frontal brain regions can reduce the overall performance decline typically seen in people with mild or early stage Alzheimer’s. Dr Scharre is a neurologist who focuses on treating patients with Alzheimer’s and other dementias. He collaborated with Dr. Ali Rezai, a neurosurgeon who specializes in neuromodulation, to conduct this clinical trial.
“This same technology has been successfully used to treat more than 135,000 patients worldwide with Parkinson’s disease. Our findings suggest that frontal network modulation to improve executive and behavioral deficits should be further studied in patients with Alzheimer’s disease,” said Dr Rezai, the former director of Ohio State’s Neurological Institute who is now leading the Rockefeller Neuroscience Institute at West Virginia University.
All three study participants showed improvement, including LaVonne Moore, 85, of Delaware, Ohio. When she entered the study in 2013, she was not doing any meal preparation. After two years of deep-brain stimulation, she could independently initiate preparations of a simple meal, assemble ingredients and cook the meal. She was able to organize an outing, including arranging transportation and destination, planning for the weather and bringing the needed money. She also regained independence to select her clothing attire, researchers noted. Her 89-year-old husband, Tom Moore, said her Alzheimer’s disease has progressed, but more slowly than he expected. “LaVonne has had Alzheimer’s disease longer than anybody I know, and that sounds negative, but it’s really a positive thing because it shows that we’re doing something right,” Mr Moore said. “She didn’t hesitate to volunteer for the study,” he added. He said she told him: “I will do anything to help others not go through what I’m going through.” Next, Ohio State researchers want to explore non-surgical methods to stimulate the frontal lobe, which would be a less invasive treatment option to slow down the symptoms of Alzheimer’s disease.
Alzheimer’s disease is the most common form of degenerative dementia, affecting more than 5 million Americans. By 2050, this number could rise as high as 16 million, according to the Alzheimer’s Association. “The disease – which has no cure and is not easily managed – becomes progressively disabling with loss of memory, cognition and worsening behavioral function, in addition to a gradual loss of independent functioning,” Dr Scharre said.
Funding for this study was provided by The Ohio State University Center for Neuromodulation, the Wright Center of Innovation in Biomedical Imaging, OTF-TECH-11-044 and philanthropic donations.
Other Ohio State researchers involved in this study include Emily Weichart, Dylan Nielson, Jun Zhang, Punit Agrawal, Per B. Sederberg and Michael V. Knopp. The authors have no conflicts of interest to report except Rezai, who declares that a patent (US 8,538,536) was issued.
NOTES TO EDITORS
Full study: Scharre DW, Weichart E, Nielson D, Zhang J, Agrawal P, Sederberg PB, Knopp MV, Rezai AR, for the Alzheimer’s Disease Neuroimaging Initiative (2018) “Deep Brain Stimulation of Frontal Lobe Networks to Treat Alzheimer’s Disease” J Alzheimers Dis 62 (2) 621–633 (DOI: 10.3233/JAD-170082).
Journalists who wish to reach the authors for comment, or to obtain the full text of the paper, should approach:
Eileen Scahill, media relations at Wexner Medical Center (+1 614-293-3737 or email@example.com)
About the Journal of Alzheimer’s Disease
Celebrating its 20th anniversary in 2018, the Journal of Alzheimer’s Disease (j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer’s Disease has an Impact Factor of 3.731 according to the 2016 Journal Citation Reports (Clarivate Analytics, 2017). The journal is published by IOS Press (iospress.com).